Literature DB >> 20865029

Urine catecholamine levels as diagnostic markers for neuroblastoma in a defined population: implications for ophthalmic practice.

S J Smith1, N N Diehl, B D Smith, B G Mohney.   

Abstract

PURPOSE: although elevated urinary catecholamine levels have been reported in 90-95% of patients with neuroblastoma, more recent studies of pediatric Horner syndrome caused by an underling neuroblastoma have reported normal values at presentation. The purpose of this population-based study is to report the percentage of cases of neuroblastoma with elevated urinary catecholamine levels at presentation and to suggest a recommended work-up for cases of idiopathic pediatric Horner syndrome.
METHODS: the medical records of all pediatric (<19 years) residents of Olmsted County, Minnesota diagnosed with neuroblastoma from 1 January 1969 through 31 December 2008 were retrospectively reviewed.
RESULTS: a total of 14 patients <19 years of age were diagnosed with neuroblastoma as residents of Olmsted County, Minnesota, during the 40-year study period. A total of 10 (71%) of the 14 cases manifested elevated urinary catecholamine metabolites at the initial presentation. Urinary vanillylmandelic acid (VMA) levels were greater than twice the upper limit of normal in eight (57%) of 14 cases, whereas homovanillic acid (HVA) levels were greater than two times the upper limit of normal in 10 (71%) of the 14 cases. Three (75%) of the four cases without significantly elevated urinary VMA or HVA levels were diagnosed with stage IV disease, whereas one (25%) had stage II neuroblastoma.
CONCLUSION: urinary catecholamine levels were significantly elevated at presentation in 10 (71%) of the 14 neuroblastoma cases during the 40-year study period, suggesting that greater emphasis be placed on performing a thorough physical examination and obtaining warranted imaging studies in cases of idiopathic pediatric Horner syndrome.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20865029      PMCID: PMC3277743          DOI: 10.1038/eye.2010.125

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  25 in total

1.  Heterochromia and Horner syndrome associated with cervical and mediastinal neuroblastoma.

Authors:  N Jaffe; R Cassady; R Petersen; D Traggis
Journal:  J Pediatr       Date:  1975-07       Impact factor: 4.406

2.  Horner's syndrome in childhood.

Authors:  C Sauer; M W Levingohn
Journal:  Neurology       Date:  1976-03       Impact factor: 9.910

3.  Ophthalmological aspects of neuroblastomatosis: a study of 53 verified cases.

Authors:  J E Alfano
Journal:  Trans Am Acad Ophthalmol Otolaryngol       Date:  1968 Nov-Dec

4.  Metastatic neuroblastoma causing bilateral blindness.

Authors:  E E Shubert; G L Oliver; N T Jaco
Journal:  Can J Ophthalmol       Date:  1969-01       Impact factor: 1.882

5.  Pediatric Horner syndrome.

Authors:  A R Jeffery; F J Ellis; M X Repka; J R Buncic
Journal:  J AAPOS       Date:  1998-06       Impact factor: 1.220

6.  The patient record in epidemiology.

Authors:  L T Kurland; C A Molgaard
Journal:  Sci Am       Date:  1981-10       Impact factor: 2.142

7.  Urinary excretion of 3-methoxy-4-hydroxymandelic acid and 3-methoxy-4-hydroxyphenylacetic acid by 288 patients with neuroblastoma and related neural crest tumors.

Authors:  E H LaBrosse; C Com-Nougué; J M Zucker; E Comoy; C Bohuon; J Lemerle; O Schweisguth
Journal:  Cancer Res       Date:  1980-06       Impact factor: 12.701

8.  Screening of infants and mortality due to neuroblastoma.

Authors:  William G Woods; Ru-Nie Gao; Jonathan J Shuster; Leslie L Robison; Mark Bernstein; Sheila Weitzman; Greta Bunin; Isra Levy; Josee Brossard; Geoffrey Dougherty; Mendel Tuchman; Bernard Lemieux
Journal:  N Engl J Med       Date:  2002-04-04       Impact factor: 91.245

9.  Occult neuroblastoma presenting with opsomyoclonus: utility of computed tomography.

Authors:  C Farrelly; A Daneman; H S Chan; D J Martin
Journal:  AJR Am J Roentgenol       Date:  1984-04       Impact factor: 3.959

10.  Initial urinary catecholamine metabolite concentrations and prognosis in neuroblastoma.

Authors:  W E Laug; S E Siegel; K N Shaw; B Landing; J Baptista; M Gutenstein
Journal:  Pediatrics       Date:  1978-07       Impact factor: 7.124

View more
  2 in total

1.  The role of N-Myc gene amplification in neuroblastoma childhood tumour - single-centre experience.

Authors:  Przemysław Kaczówka; Aleksandra Wieczorek; Małgorzata Czogała; Teofila Książek; Katarzyna Szewczyk; Walentyna Balwierz
Journal:  Contemp Oncol (Pozn)       Date:  2018-12-31

2.  Paediatric Horner Syndrome: How much further to investigate?

Authors:  Manjushree Bhate; Maree Flaherty; Neil Rowe; Robert Howman-Giles
Journal:  Indian J Ophthalmol       Date:  2020-11       Impact factor: 1.848

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.